Remarkably, in the present study, APOA2 levels were also reduced in critical patients compared to mild ones (Table S2), which is in agreement with the findings of a systematic review reporting that adequate levels of APOA1 were related to a protection against mortality in patients hospitalized for COVID-19 [37]. The gene discussed is APOA1; the disease is COVID-19.